---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-092205"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2023-08-16T23:59:59+00:00"
generated_at: "2026-06-11T08:21:53.635716+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# TELA Bio launches OviTex PRS Long-Term Resorbable for plastic and reconstructive surgery

## Summary
- OviTex PRS Long-Term Resorbable is intended for soft tissue repair or reinforcement in plastic and reconstructive surgery.
- Product supplements existing OviTex PRS portfolio which includes Permanent and Short-Term Resorbable configurations.
- Features include bi-directional stretch and a fully resorbable, long-term polymer for reinforcement.
- OviTex PRS has over 6,800 implantations at more than 400 healthcare facilities.
- CEO Antony Koblish says addition allows surgeons to address indications requiring longer term reinforcement without permanent materials.

## SEC filing metadata
- accession: 0001104659-23-092205
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2023-08-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465923092205/0001104659-23-092205-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465923092205/tm2323862d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-092205
- JSON: https://secwatch.observer/filing/0001104659-23-092205.json
- Plain text: https://secwatch.observer/filing/0001104659-23-092205.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.